Introduction
============

Colorectal cancer (CRC) causes high morbidity and mortality rates; however, both declined the last four decades in Western countries \[[@b1-crt-2019-008]\]. Cancer prevention could be attributed through screening at an early stage and more effective treatment modalities. Moreover, it was shown that patients with high-risk stage II and stage III colon cancer (CC) who received the current standard treatment according to the National Comprehensive Cancer Network guidelines had a benefit on their survival rates \[[@b2-crt-2019-008]\].

For stage III disease, combination chemotherapy with a backbone of fluoropyrimidine and oxaliplatin (FOLFOX, CAPOX) is the current standard of care, since it leads to prolongation of both disease-free survival (DFS) and overall survival (OS) \[[@b3-crt-2019-008]\]. The results for the addition of oxaliplatin in OS and DFS for patients with stage II CC with high-risk features (such as T4 tumors, obstruction or perforation, and vessel invasion) showed a marginal but significant \[[@b3-crt-2019-008]\]. Despite that, it has long been recognized patients' individual risk of recurrence varies widely even in patients with the same stage in CC. Since today, microsatellite instability (MSI) status is the only biomarker used in daily clinical practice \[[@b4-crt-2019-008]\].

Several studies have reported that germline inactivating mutations in liver kinase b1 (LKB1) to be the primary cause syndromes, such as the Peutz-Jeghers syndrome, which confer an increased risk of cancer development \[[@b5-crt-2019-008],[@b6-crt-2019-008]\]. The LKB1 also known as serine threonine kinase 11 (STK11), was initially discovered as a tumor suppressor gene and it has been implicated on initiation and progression of neoplastic diseases \[[@b5-crt-2019-008]\]. It controls a wide range of diverse cellular processes through phosphorylation of the adenosine monophosphate-activated protein kinase (AMPK) protein when cellular energy levels are depleted promoting ATP \[[@b6-crt-2019-008]\]. Furthermore, loss of LKB1 has been shown to influence cell polarity, epi-thelial-to-mesenchymal transition, apoptosis, angiogenesis, and cell cycle inhibition \[[@b7-crt-2019-008]\]. Also, negatively regulates the mammalian target of rapamycin signaling \[[@b5-crt-2019-008]\] and mediates p53 activation \[[@b8-crt-2019-008]\]. LKB1 has been most intensively studied using lung cancer mouse models \[[@b9-crt-2019-008]\]. Finally, the results of a first comprehensive meta-analysis suggested that decreased LKB1 expression significantly contributed to shorter OS in solid tumor patients \[[@b10-crt-2019-008]\]. However, additional studies rela-ted to specific tumor types and perspectives are required to verify the clinical utility of decreased LKB1 levels in solid tumors.

Based on the above-mentioned data we conducted a retrospective biomarkers-based studies, in order to elucidate the clinicopathological features and prognostic significance of LKB1 loss of expression in high-risk stage II and stage III CC, treated with oxaliplatin and fluoropyrimidine combination adjuvant chemotherapy.

Materials and Methods
=====================

1. Patients' population
-----------------------

Two hundred and two formalin-fixed, paraffin-embedded samples from consecutive patients with stage III or high-risk stage II CC treated with FOLFOX or CAPOX has been studied.

2. Specimens' selection, DNA and RNA extraction
-----------------------------------------------

The most enriched in cancer cells areas were selected by a pathologist (M.T.) and afterwards, serial sections of 5 μm were stained by nuclear Fast Red (Sigma-Aldrich, St. Louis, MO). Micro-dissection, using a piezoelectric micro-dissector (Eppendorf, Hamburg, Germany) was performed in cases with lower than 80% of neoplastic cells in the examined section. Extraction of nucleic acids (DNA and RNA) was performed, according to the manufacturer's protocol as previously described \[[@b11-crt-2019-008]\].

3. *KRAS* and *BRAF* mutational analysis
----------------------------------------

*KRAS* exon 2 and *BRAF*^V600E^ mutation mutations analysis was carried out by Sanger sequencing after polymerase chain reaction (PCR) amplification and by reverse transcription PCR using allelic discrimination method, respectively, as previously described as previously reported \[[@b11-crt-2019-008],[@b12-crt-2019-008]\]. Analysis was performed using the SDS 2.3 software \[[@b13-crt-2019-008]\].

4. MSI status
-------------

The MSI analysis was carried out with the use of Promega MSI Analysis System (Promega, Madison, WI) according to the manufacturer's instructions. Amplicons for MSI detection was performed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer following PCR amplification and analyzed using GeneMapper Software, ver. 3.7 (Applied Biosystems/Life Technologies, Grand Island, NY) \[[@b14-crt-2019-008]\].

5. mRNA expression analysis
---------------------------

Synthesis of cDNA was done as described previously \[[@b15-crt-2019-008]\]. Primers and probes were designed using the Primer Express 2.0 Software (Applied Biosystems) according to the Ref Seq NM_002467.4 for *MYC-ERCC1-NEDD9-TS*. The sets of primers probes are provided in [S1 Table](#SD1-crt-2019-008){ref-type="supplementary-material"}, while those for the housekeeping genes, *β-actin* and *PGK* have been previously published \[[@b13-crt-2019-008]\]. The quantification of mRNA expression was carried out using the 2^−(ΔCT\ sample−ΔCT\ calibrator)^ method, as previously described \[[@b13-crt-2019-008]\]. Only triplicates with a standard deviation less than 0.25 were accepted.

6. Immunohistochemistry of LKB1
-------------------------------

We performed immunostain using Thermo Scientific UltraVision Quanto Detection System HRP and polyclonal antibody for LKB1 (1:100 dilution, Thermo Scientific, Waltham, MA). Adult seminiferous tubules of the testis were used as a positive control as it shows the highest levels of LKB1 expression \[[@b16-crt-2019-008]\]. Negative control was obtained by omitting the primary antibody. Immunohistochemistry (IHC) staining intensity was measured using a scaling system of 0 (no expression), 1, 2, and 3 (highest expression) blinded by a pathologist. A weighted index (WI) was applied in both the nucleus and the cytoplasm using the equation WI=% tumor stain X intensity score as used in another study \[[@b16-crt-2019-008]\]. Cytoplasmic, nuclear expression or both were considered a positive stain. The staining of LKB1 was interpreted without knowledge of its genetic status.

7. Study design and statistical analysis
----------------------------------------

DFS was estimated as the interval between the date of colectomy to the first documented disease progression, second primary CC or death. OS was calculated from the date of surgery to date of death. The Kaplan-Meier survival curves were used for survival analysis and correlations with the studied parameters, while Cox proportional hazards model was applied to weigh the validity of considered factors on study defined events. The statistically significant factors were then incorporated in a multivariate Cox proportional hazards regression model in order to estimate their unbiased significance on progression or survival. The only p-value of \< 0.05 was considered as significant.

The median values of mRNA expression were used as cut-off points, with samples above or equal to the median characterized as high expressing, while those with value below the median as low expression. The laboratory research was completed blinded to the clinical parameters. Correlations between the studied biomarker with baseline characteristics were calculating by Fisher exact test for categorical variables or logistic regression for continuous ones.

8. Ethical statement
--------------------

The study has been approved by the Ethics and Scientific Committees of the University General Hospital of Heraklion (number of approval: 2058) and written informed consent for the use of their tissue for translational research was obtained from all patients. All authors, declare no competing interest regarding this study.

Results
=======

1. Patients' characteristics and clinicopathological features
-------------------------------------------------------------

The main demographic and clinical characteristics of the study population are summarized in [Table 1](#t1-crt-2019-008){ref-type="table"}. Briefly, patients with CC were predominately males (58%), with a median age of 67 years and the majority of them with a good performance status of 0-1. In addition, 60% of the patients were diagnosed with stage III colon cancer, 65% had primary tumor located in the left colon and 61% low-grade tumors ([Table 1](#t1-crt-2019-008){ref-type="table"}). Almost two-thirds of the patients (65%) received adjuvant treatment with CAPOX and the rest one third with FOLFOX. At the time of analysis and after a median follow-up of 120.7 months (min-max, 11.3 to 161.1 months); 71 (27%) disease relapses and 48 (18%) deaths have been recorded.

2. Laboratory analysis and correlations
---------------------------------------

The results of the laboratory analysis are presented in [Table 2](#t2-crt-2019-008){ref-type="table"}. Analysis for LKB1 protein expression was successfully performed in all 254 specimens (96.9%), whereas *KRAS* exon 2 and *BRAF* exon 15 mutation analysis was performed in 251 (95.8%) and 246 (93.9%) specimens,respectively ([Table 2](#t2-crt-2019-008){ref-type="table"}, [S2](#SD2-crt-2019-008){ref-type="supplementary-material"}-[S5 Figs](#SD5-crt-2019-008){ref-type="supplementary-material"}.). Mismatch repair (MMR) system status was successfully analyzed in 235 (89.7%) specimens, while mRNA expression of *ERCC1*, *MYC*, *NEDD9*, and *TS* was successfully done in 247 (94.3%), 250 (95.4%), 249 (95%), and 226 (86.2%) specimens, respectively ([S6 Fig](#SD6-crt-2019-008){ref-type="supplementary-material"}.).

Loss of LKB1 protein expression was observed in 117 (44.7%) tumors and correlated significantly with pericolic lymph node involvement (p=0.003) and primary tumors located in the right colon (p=0.032), whereas no significant correlation of LKB1 protein expression with age, sex, and grade were found ([Table 3](#t3-crt-2019-008){ref-type="table"}). In addition, LKB1 protein expression loss was significantly correlated with *BRAF*^V600E^ mutation (p=0.024), and *TS* mRNA (p=0.041). In contrast, LKB1 protein expression loss was not significantly associated with *KRAS* exon 2 mutations, MMR status or *ERCC1*, *MYC*, *NEDD9* mRNA expression (all p \> 0.05).

3. Laboratory analysis and patients' outcome
--------------------------------------------

The correlations of analyzed markers and clinic-pathological features with DFS and OS are presented in [Tables 4](#t4-crt-2019-008){ref-type="table"} and [5](#t5-crt-2019-008){ref-type="table"}, respectively. Patients with tumors with LKB1 expression loss showed significantly lower DFS compared with those with LKB1 positive tumors (hazard ratio \[HR\], 1.287; 95% confidence interval \[CI\], 1.093 to 1.654; p=0.021) ([Table 4](#t4-crt-2019-008){ref-type="table"}, [Fig. 1](#f1-crt-2019-008){ref-type="fig"}). In addition, patients with *BRAF*^V600E^ mutations in their primary tumors presented higher probability for relapse compared to patients with *BRAF*^V600E^ wild type tumors (HR, 1.976; 95% CI, 1.793 to 2.495; p=0.001) ([Table 4](#t4-crt-2019-008){ref-type="table"}). Likewise, patients with *KRAS* exon 2 mutations in their primary tumors presented higher probability for relapse compared to patients with *KRAS* exon 2 wild type tumors, but the difference was marginally significant (HR, 1.757; 95% CI, 1.000 to 3.090; p=0.05). Furthermore, patients with proficient MMR (pMMR) tumor had a significantly higher risk of relapse in comparison with those with deficient MMR (dMMR) tumors (HR, 1.726; 95% CI, 1.289 to 3.514; p=0.025). Finally, stage III disease at diagnosis is correlated with increased risk of progression compared with stage II (HR, 1.803; 95% CI, 1.605 to 2.055; p=0.023). All other comparisons between the mRNA expression of the *ERCC1*, *MYC*, *NEDD9*, and *TS* or several clinicopathological features, such as age, sex, tumor location and grade, did not reveal any significant correlations with DFS (all long-rank p \> 0.05).

Regarding OS, patients with tumors with LKB1 expression loss showed significantly lower OS compared with those with LKB1 positive tumors (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002) ([Table 4](#t4-crt-2019-008){ref-type="table"}, [Fig. 2](#f2-crt-2019-008){ref-type="fig"}). Similarly, patients with *BRAF*^V600E^ mutations in their primary tumors presented higher probability for death compared to patients with *BRAF*^V600E^ mutations wild type tumors (HR, 1.624; 95% CI, 1.143 to 2.309; p=0.007) ([Table 4](#t4-crt-2019-008){ref-type="table"}). In addition, patients with pMMR tumor had a significantly higher risk of death in comparison with those with dMMR tumors (HR, 1.375; 95% CI, 1.043 to 2.711; p=0.036). Also, stage III disease at diagnosis is correlated with increased risk of progression compared with stage II (HR, 1.636; 95% CI, 1.487 to 2.011; p=0.03). All other comparison did not reveal any significant correlations between the mRNA expression of the *ERCC1*, *MYC*, *NEDD9*, and *TS* or the detection of *KRAS* exon 2 mutation as well as clinicpathological features, such as age, sex, tumor location and grade, with DFS (all long-rank p \> 0.05).

Multivariate analysis for DFS, revealed that LKB1 expression loss (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) ([Table 5](#t5-crt-2019-008){ref-type="table"}), *BRAF*^V600E^ mutations (HR, 1.696; 95% CI, 1.365 to 2.294; p=0.011), pMMR status (HR, 1.775; 95% CI, 1.343 to 3.011; p=0.007) and stage III disease (HR, 1.784; 95% CI, 1.335 to 2.762; p=0.006) as independent factors for increased risk of relapse. Similarly, LKB1 expression loss (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019), *BRAF*^V600E^ mutations (HR, 1.961; 95% CI, 1.656 to 2.949; p=0.001), pMMR status (HR, 1.575; 95% CI, 1.243 to 3.001; p=0.018), and stage III disease (HR, 1.843; 95% CI, 1.356 to 2.623; p=0.009) was statistically associated with risk of death.

Discussion
==========

The data presented in the current study, demonstrated for the first time in literature, the impact of testing LKB1 protein expression in stage II/III CC patients that underwent resection and subsequently received CAPOX or FOLFOX adjuvant chemotherapy. Additionally, this retrospective study aims to identify correlations of LKB1 expression loss with known clinic-pathological features and common mutations (*KRAS* exon 2 and *BRAF*^V600E^) mutation in operable CC. Moreover, we analyzed the predictive significance of these biomarkers in conjunction with *ERCC1*, *MYC*, *NEDD9*, and *TS* mRNA expression. Based on the literature, this is the first study that correlates a combination of all these parameters, hence; the results of our analysis could potentially serve as an advantageous guide for every day clinical practice.

AMPK is greatly regulated by LKB1 activity and is vital for cell metabolism through the maintenance of energy homeostasis. LKB1 growth-suppressing effect is operated through activation of twelve AMPK-related kinases. This AMPK-related kinases activation by LKB1 is crucial for the regulation of (1) cell metabolism, (2) polarity, and (3) aberrant proliferation inhibition in malignant cells \[[@b17-crt-2019-008]\], indicating the role of LKB1 as a tumor suppressor gene \[[@b18-crt-2019-008]\]. Therefore, LKB1 loss promotes cancer evolution and is considered a negative factor in cancer patients \[[@b19-crt-2019-008]\]. The results of the present investigation indicate, that stage II-III CC patients with loss of LKB1 protein expression exhibited significantly lower DFS (p=0.021) and lower OS (p=0.002) compared to those with LKB1 positive tumors. Thus, the principal finding emerged from the current multivariate analysis, is the prognostic value of LKB1 in adjuvant CRC patients.

It is previously well described, that LKB1 loss confers poor clinical outcome in human gastric cancer, breast cancer and hepatocellular carcinoma \[[@b18-crt-2019-008],[@b20-crt-2019-008],[@b21-crt-2019-008]\]. Furthermore, in 14 eligible studies that met the inclusion criteria, a first comprehensive meta-analysis demonstrated that the decreased LKB1 expression was significantly associated with a poorer OS in solid tumor patients, based on a random effect model \[[@b10-crt-2019-008]\]. Previous research has demonstrated that *LKB1* loss at the transcriptional level, promotes tumor malignancy, not only in lung adenocarcinoma but also in CRC \[[@b22-crt-2019-008]\]. Another study has revealed that reduced *LKB1* expression in patients with gastric cancer is correlated with higher clinical stage, T-stage, lymph-node metastasis and vascular invasion \[[@b21-crt-2019-008]\]. Similarly, in the present study, a significant correlation of LKB1 loss with certain pathological and clinical parameters of CRC was observed, such as pericolic lymph node involvement (p=0.003) and primary tumors located in the right colon (p=0.032). In contrast, no significant correlation of LKB1 protein expression associated with age, gender and grade was revealed.

The present study failed to demonstrate any statistically significant correlation between LKB1 protein expression and *KRAS* exon 2 mutation, as has been previously reported in lung adenocarcinomas \[[@b23-crt-2019-008]\]. On the other hand, our analysis demonstrated significant correlations of LKB1 loss with *BRAF*^V600E^ mutation and high *TS* mRNA expression.

In support to previous data that have correlated factors such as KRAS and *BRAF*^V600E^ mutations, pMMR positive tumors and stage III disease status, with a higher probability of relapse, our results clearly demonstrate that *BRAF*^V600E^ mutations, pMMR tumors and patients with stage III disease at diagnosis are associated with lower DFS and OS. Although the expression of *ERCC1* and *TS* genes has been shown to be involved in the metabolism of the two main drug categories used in the adjuvant CRC setting, such as oxaliplatin and 5-fluorouracil, respectively \[[@b24-crt-2019-008],[@b25-crt-2019-008]\], the current study did not reveal any significant correlation between the *ERCC1* and *TS* mRNA expression and the patients' outcome. Despite the previously identified prognostic value of *NEDD9* and *MYC* in CC patients \[[@b26-crt-2019-008],[@b27-crt-2019-008]\], the current analysis failed to reveal any significant correlation between the *NEDD9* and *MYC* mRNA expression with either DFS or OS in patients with CC receiving adjuvant chemotherapy.

The prognostic or predictive value of LKB1 expression loss in patients with CC is currently unknown. As reported in a previous study, this could be due to the wide range of *LKB1* genomic alterations observed in sporadic cancers, emerging the challenge of developing a single assay capable of the detection of all these alterations combined \[[@b28-crt-2019-008]\]. Moreover, Sanchez-Cespedes \[[@b29-crt-2019-008]\] reported that many different types of *LKB1* somatic mutations in sporadic cancers have been identified including insertions, deletions, nonsense, and frameshift and missense mutations. However, most of the *LKB1* genomic alterations can result in either a truncated and therefore inactive form of the protein \[[@b28-crt-2019-008],[@b29-crt-2019-008]\] or the complete absence of the protein. To overcome such a limitation, we considered the *in-situ* IHC assay as a potentially trustworthy, simple, and cost-effective method for evaluating the expression status of LKB1.

Besides, the robust results for LKB1 expression loss and the large patients' number of the current study, the finding should be interpreted with caution and mainly as hypothesis generated results. One of the main limitations is the lack of validation sets of patients treated or not treated with adjuvant chemotherapy, in order to elucidate the potential prognostic or predictive role of LKB1 expression loss in CC. Consequently, the design of an independent prospective validation trial is one of the future perspectives of our laboratory, where the prognostic power of LKB1 expression loss would be tested and validated prospectively. In summary, the results of the presented study indicate that loss of LKB1 protein expression is clearly associated with poor outcomes of patients with stage III or high-risk stage II CC and merits further evaluation in larger prospective patients' cohorts.
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###### 

Sequence of the primers and probes of all reference and target genes

###### 

LKB1 positive cytoplasmatic expression in normal mucosa (score 1), intense expression in tumor cells (score 3) (×200).

###### 

(A, B) LKB1 cytoplasmatic expression in tumor cells (×200). (C, D) LKB1 cytoplasmic and nuclear expression in tumor cells (×200). (E, F) Exclusive nuclear expression of LKB1 in tumor cells (E, ×200; F, ×100).

###### 

Negative expression of LKB1 protein in adenocarcinoma (×100).

###### 

LKB1 positive expression in normal crypts of large bowel intestine, negative expression in colon adenocarcinoma (×100).

###### 

Quantification of β-actin (internal control gene) and TS (gene of interest) mRNA by real-time quantitative reverse transcription polymerase chain reaction (representative image) in the ABI Prism 7900HT. The panel illustrates the logarithmic plot of fluorescence signal during amplification.

![Disease-free survival according to LKB1 protein expression loss by immunohistochemistry. DFS, disease-free survival; HR, hazard ratio; CI, confidence interval.](crt-2019-008f1){#f1-crt-2019-008}

![Overall survival according to LKB1 protein expression loss by immunohistochemistry. HR, hazard ratio; CI, confidence interval.](crt-2019-008f2){#f2-crt-2019-008}

###### 

Stage II or III patients: clinical characteristics and pathological features

  Feature                                              No. (%) (n=262)
  ---------------------------------------------------- -----------------
  **Age, median (range, yr)**                          67 (33-75)
   ≤ 70                                                162 (62.0)
   \> 70                                               100 (38.0)
  **Sex**                                              
   Male                                                152 (58.0)
   Female                                              110 (42.0)
  **Performance status (ECOG)**                        
   0                                                   196 (75.0)
   1                                                   66 (25.0)
  **Stage**                                            
   IIa                                                 90 (34.0)
   IIb                                                 14 (6.0)
   IIIa                                                19 (7.0)
   IIIb                                                81 (31.0)
   IIIc                                                58 (22.0)
  **Tumor grade**                                      
   Low                                                 160 (61.0)
   High                                                102 (39.0)
  **Primary tumor (T)**                                
   T2                                                  27 (10.3)
   T3                                                  216 (82.4)
   T4                                                  19 (7.3)
  **Mucinous**                                         
   Yes                                                 59 (23.0)
   No                                                  203 (77.0)
  **Obstruction**                                      27 (10.0)
  **Perforation**                                      40 (15.0)
  **Location**                                         
   Right sided                                         91 (35.0)
   Left sided                                          171 (65.0)
  **Regimen**                                          
   CAPOX                                               171 (65.0)
   FOLFOX                                              91 (35.0)
  **No. of retrieved lymph nodes, median (min-max)**   15 (6-108)
  **No. of positive lymph nodes, median (min-max)**    1 (0-18)

###### 

Laboratory analysis

  Feature                       No. (%) (n=262)
  ----------------------------- -----------------
  **LKB1 protein expression**   
   Negative                     117 (44.7)
   Positive                     137 (52.3)
   Failed                       8 (3.1)
  ***ERCC1* mRNA expression**   
   Low                          124 (47.3)
   High                         123 (46.9)
   Failed                       15 (5.7)
  ***MYC* mRNA expression**     
   Low                          125 (47.7)
   High                         125 (47.7)
   Failed                       12 (4.6)
  ***NEDD9* mRNA expression**   
   Low                          125 (47.7)
   High                         124 (47.3)
   Failed                       13 (5.0)
  ***TS* mRNA expression**      
   Low                          113 (43.1)
   High                         113 (43.1)
   Failed                       36 (13.8)
  ***BRAF*^V600E^ status**      
   WT                           233 (88.9)
   Mutant                       13 (5.0)
   Failed                       16 (6.1)
  ***KRAS* exon 2 mutation**    
   WT                           169 (64.5)
   Mutant                       82 (31.3)
   Failed                       11 (4.2)
  **MMR status**                
   Proficient                   200 (76.3)
   Deficient                    35 (13.4)
   Failed                       27 (10.3)

MMR, mismatch repair.

###### 

Correlation of LKB1 expression with patients' characteristics and tumor's features and DNA markers

  LKB1 protein expression (n=254)       Negative (n=117)   Positive (n=137)   p-value
  ------------------------------------- ------------------ ------------------ ------------------------------------------------------
  **Age, median (min-max, yr)**         65 (33-75)         67 (37-75)         0.147^[a)](#tfn1-crt-2019-008){ref-type="table-fn"}^
  **Age group (yr)**                                                          
   ≤ 70                                 72 (61.5)          86 (62.8)          0.897^[b)](#tfn2-crt-2019-008){ref-type="table-fn"}^
   \> 70                                45 (38.5)          51 (37.2)          
  **Sex**                                                                     
   Male                                 72 (61.5)          74 (54.0)          0.253^[c)](#tfn3-crt-2019-008){ref-type="table-fn"}^
   Female                               45 (38.5)          63 (46.0)          
  **Lymph node status**                                                       
   N0                                   33 (28.2)          68 (49.6)          0.003^[b)](#tfn2-crt-2019-008){ref-type="table-fn"}^
   N1-2                                 84 (71.8)          69 (50.4)          
  **Tumor location**                                                          
   Right                                49 (41.9)          41 (29.9)          0.032^[b)](#tfn2-crt-2019-008){ref-type="table-fn"}^
   Left                                 68 (58.1)          96 (70.1)          
  **Primary tumor (T)**                                                       
   T2-T3                                74 (36.8)          114 (56.7)         0.008^[b)](#tfn2-crt-2019-008){ref-type="table-fn"}^
   T4                                   10 (5.0)           3 (1.5)            
  **Grade**                                                                   
   Low grade                            70 (59.8)          90 (65.7)          0.880^[b)](#tfn2-crt-2019-008){ref-type="table-fn"}^
   High grade                           47 (38.5)          47 (34.3)          
  ***BRAF*^V600E^ status (n=236)**      ND 7               ND 11              
   Wild type (n=223)                    100 (90.9)         123 (97.6)         0.024
   Mutant (n=13)                        10 (9.1)           3 (2.4)            
  ***KRAS* exon 2 (n=246)**             ND 6               ND 5               
   Wild type (n=224)                    70 (62.7)          91 (70.1)          0.328
   Mutant (n=22)                        41 (37.3)          41 (29.9)          
  **MMR status (n=235)**                ND 9               ND 16              
   Proficient                           96 (88.9)          99 (81.8)          0.102
   Deficient                            12 (11.1)          22 (18.2)          
  ***ERCC1* mRNA expression (n=246)**   ND 4               ND 4               
   High                                 59 (52.2)          69 (51.9)          0.609
   Low                                  54 (47.8)          64 (48.1)          
  ***MYC* mRNA expression (n=249)**     ND 2               ND 3               
   High                                 55 (47.8)          69 (51.5)          0.612
   Low                                  60 (52.2)          65 (48.5)          
  ***NEDD9* mRNA expression (n=247)**   ND 3               ND 4               
   High                                 58 (50.9)          64 (48.1)          0.703
   Low                                  56 (49.1)          69 (51.9)          
  ***TS* mRNA expression (n=226)**      ND 15              ND 13              
   High                                 58 (56.9)          49 (39.5)          0.041
   Low                                  44 (43.1)          75 (60.5)          

Values are presented as number (%). MMR, mismatch repair.

Mann-Whitney test,

Pearson chi-square,

Fisher exact test.

###### 

Univariate analysis for median disease-free and overall survival

                                                    Disease-free survival   Overall survival                                 
  ------------------------------------------------- ----------------------- ------------------ ------- ------- ------------- -------
  LKB1 protein expression (negative vs. positive)   1.287                   1.093-1.654        0.021   1.541   1.197-1.932   0.002
  *KRAS* exon2 mutations (mutant vs. wild type)     1.757                   1.000-3.090        0.050   1.190   0.607-2.335   0.113
  *BRAF*^V600E^ mutation (mutant vs. wild type)     1.976                   1.793-2.495        0.001   1.624   1.143-2.309   0.007
  MMR status (proficient vs. deficient)             1.726                   1.289-3.514        0.025   1.375   1.043-2.711   0.036
  *ERCC1* mRNA expression (high vs. low)            1.164                   0.610-1.570        0.930   1.003   0.558-1.802   0.993
  *MYC* mRNA expression (high vs. low)              1.179                   0.735-1.892        0.494   1.170   0.856-1.598   0.324
  *NEDD9* mRNA expression (high vs. low)            1.070                   0.634-1.219        0.343   1.068   0.601-1.895   0.823
  *TS* mRNA expression (high vs. low)               1.701                   0.804-2.598        0.165   1.113   0.472-2.625   0.807
  Stage III vs. II                                  1.803                   1.605-2.055        0.023   1.636   1.487-2.011   0.030
  Tumor location                                    1.131                   0.683-1.873        0.632   1.016   0.557-1.851   0.906
  Age (\> 70 yr vs. ≤ 70 yr)                        1.035                   0.641-1.673        0.887   1.207   0.938-1.843   0.106
  Sex (men vs. women)                               1.176                   0.915-1.804        0.112   1.011   0.981-1041    0.471
  Grade (high vs. low)                              1.061                   0.872-1.201        0.722   1.108   0.536-2.209   0.781

CI, confidence interval; MMR, mismatch repair.

###### 

Multivariate analysis for median disease-free and overall survival

                                                    Disease-free survival   Overall survival                                 
  ------------------------------------------------- ----------------------- ------------------ ------- ------- ------------- -------
  LKB1 protein expression (negative vs. positive)   1.217                   1.074-1.812        0.034   1.467   1.226-2.122   0.019
  *KRAS* exon2 mutations (mutant vs. wild type)     1.054                   0.816-1.806        0.317   \-      \-            \-
  *BRAF*^V600E^ mutation (mutant vs. wild type)     1.696                   1.365-2.294        0.011   1.961   1.656-2.949   0.001
  MMR status (proficient vs. deficient)             1.775                   1.343-3.011        0.007   1.575   1.243-3.001   0.018
  Stage III vs. II                                  1.784                   1.335-2.762        0.006   1.843   1.356-2.623   0.009

CI, confidence interval; MMR, mismatch repair.
